(Q57695982)

2

0 references

Jenny Heathcote

3

0 references

Linda Scully

4

0 references

Leonard Seeff

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

5

0 references

publication date

January 2004

0 references

published in

Medical Decision Making

0 references

volume

24

0 references

page(s)

20-29

0 references

issue

1

0 references

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Primer on Medical Decision Analysis: Part 5—Working with Markov Processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Meta-analysis in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Probabilistic analysis of decision trees using symbolic algebra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

The natural history of transfusion-associated infection with human immunodeficiency virus. Factors influencing the rate of progression to disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Antibody to Hepatitis C Virus among Cardiac Surgery Patients, Homosexual Men, and Intravenous Drug Users in Baltimore, Maryland

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Non-A, non-B post-transfusion hepatitis. Looking back in the second decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Predictors of patient and graft survival following liver transplantation for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Long-term outcome of hepatitis C infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Indications for interferon/ribavirin therapy in hepatitis C patients: findings from a survey of Canadian hepatologists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

NHS told to pay 10m (pounds sterling) to patients infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Epidemiology and long term prognosis of hepatitis C virus infection in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Preliminary report on 10 patients treated with radiotherapy after radical prostatectomy for isolated elevation of serum PSA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568

The long-term pathological evolution of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X03261568